Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 2/20 | 0.51 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.51 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | GJB2 | P29033 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | FGF1 | P05230 | 2/20 | 0.37 |
| ▸ | FGF2 | P09038 | 2/20 | 0.37 |
| ▸ | VEGFA | P15692 | 2/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15502120 | 1.00 | SSTR5 (0.51) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL11921409 | 1.00 | SSTR5 (0.51) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL14999636 | 1.00 | SSTR5 (0.51) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL15871629 | 1.00 | SSTR5 (0.51) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL2621331 | 1.00 | SSTR5 (0.51) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16367561 | 0.96 | SSTR5 (0.50) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL14370515 | 0.96 | SSTR1 (0.53) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL17174992 | 0.96 | SSTR5 (0.50) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL26879259 | 0.94 | SSTR5 (0.49) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL26877148 | 0.93 | SSTR1 (0.47) | SSTR5SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012428-B2 | Uracyl spirooxetane nucleoside phosphoramidates | JANSSEN PRODUCTS, LP (US) | 2015-04-21 | — | — | US | disclosed |
| US-9006209-B2 | Uracyl spirooxetane nucleoside phosphoramidates | JANSSEN PRODUCTS, LP (US) | 2015-04-14 | — | — | US | disclosed |
| US-8933052-B2 | Uracyl spirooxetane nucleosides | JANSSEN PRODUCTS, LP (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130244968-A1 | Uracyl Spirooxetane Nucleoside Phosphoramidates | TIBOTEC BVBA (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130225520-A1 | Uracyl Spirooxetane Nucleoside Phosphoramidates | TIBOTEC BVBA (BE) | 2013-08-29 | — | — | US | disclosed |
| US-20130217648-A1 | Uracyl Spirooxetane Nucleosides | MEDIVIR AB (SE) | 2013-08-22 | — | — | US | disclosed |
| US-8481510-B2 | Uracyl spirooxetane nucleosides | JANSSEN PRODUCTS, LP (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8242085-B2 | Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120065156-A1 | Uracyl Spirooxetane Nucleosides | TIBOTEC BVBA (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20110002886-A1 | TETRAHYDROFURO [3,4-D] DIOXOLANE COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND CANCER | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244968-A1 | Uracyl Spirooxetane Nucleoside Phosphoramidates | NUDT1, UMPS, NUDT14 | SSTR5 1345/4885SSTR1 1721/4885SSTR2 2189/4885 |
| US-20130225520-A1 | Uracyl Spirooxetane Nucleoside Phosphoramidates | NUDT1, NUDT14, UMPS | SSTR5 2552/4885SSTR1 2931/4885SSTR2 3467/4885 |
| US-20120065156-A1 | Uracyl Spirooxetane Nucleosides | PNP, NUDT1, UMPS | SSTR5 1263/4885SSTR1 877/4885SSTR2 1981/4885 |
| US-20130217648-A1 | Uracyl Spirooxetane Nucleosides | PNP, NUDT1, UMPS | SSTR5 1263/4885SSTR1 877/4885SSTR2 1981/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | SSTR5 3037/4885SSTR1 4452/4885SSTR2 4263/4885 |
| US-20110002886-A1 | TETRAHYDROFURO [3,4-D] DIOXOLANE COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND CANCER | FDFT1, DHODH, DHPS | SSTR5 2761/4885SSTR1 3801/4885SSTR2 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.